Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
- Antibody screening finds COVID-19 nearly 7 times more prevalent in O.C. than thought
- Brazilian researchers discover how muscle regenerates after exercise
- High-sugar diet can damage the gut, intensifying risk for colitis
- A drop in temperature
- Dull-colored birds don’t see the world like colorful birds do